L‐Dopa pharmacokinetics studied with microdialysis in patients with Parkinson's disease and a history of malignant melanoma
L‐Dopa pharmacokinetics studied with microdialysis in patients with Parkinson's disease and a history of malignant melanoma
复制标题
DOI：
10.1111/j.1600-0404.1999.tb00386.x
复制
发表时间：
1999-10
影响因子：
3.5
通讯作者：
N. Dizdar;A. Granérus;U. Hannestad;A. Kullman;A. Ljungdahl;J. Olsson;B. Kågedal
中科院分区：
文献类型：
--
作者：
N. Dizdar;A. Granérus;U. Hannestad;A. Kullman;A. Ljungdahl;J. Olsson;B. Kågedal
Objectives ‐ The pharmacokinetics of freel‐dopa in blood and tissue of five parkinsonian patients with malignant melanoma was studied with microdialysis. In one case the effect ofl‐dopa treatment on 5‐S‐cysteinyldopa and the melanoma was studied. Gastric emptying and its effects on free l‐dopa in blood were also investigated in one of the patients. Methods ‐ Five patients were given 100 mg l‐dopa with 25 mg benserazide. Blood and dialysates from the circulation and fatty tissue were collected for analysis. [13C]‐Octanoic breath test was used for analyzing gastric half‐emptying time. Results ‐ Four of the patients had similar pharmacokinetic patterns for l‐dopa and a significant (P < 0.05) increase of serum 5‐S‐cysteinyldopa occurring 30 min after l‐dopa intake. Delayed l‐dopa peaks and slow gastric half‐emptying time were found in 1 patient. A dose‐dependent increase of 5‐S‐cysteinyldopa occurred but no melanoma metastases were seen during long‐term l‐dopa therapy. Conclusion ‐ l‐dopa therapy increases 5‐S‐cysteinyldopa levels but does not seem to cause progress of melanomas. Gastric emptying impacts l‐dopa pharmacokinetics.
